Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remestemcel-L safety follow-up in pediatric SR-aGVHD
NCT02652130Phase 3Completed
- Sponsor
- Mesoblast Ltd
- Start
- Oct 2015
- Primary completion
- Jun 2018
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of remestemcel-L-rknd in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Mesoblast Ltd. Primary endpoint: Overall Survival Rate Through Day 180. Started Oct 2015; status: completed.
02
Drugs
remestemcel-L-rknd
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02652130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652130.